NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Applied Materials, Inc. (NASDAQ:AMAT), MRC Global Inc. (NYSE:MRC), Meritor, Inc. (NYSE:MTOR), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Quaker Chemical Corporation (NYSE:KWR), and Cubic Corporation (NYSE:CUB), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

AMAT DOWNLOAD: http://Capital-Review.com/register/?so=AMAT
MRC DOWNLOAD: http://Capital-Review.com/register/?so=MRC
MTOR DOWNLOAD: http://Capital-Review.com/register/?so=MTOR
CLDX DOWNLOAD: http://Capital-Review.com/register/?so=CLDX
KWR DOWNLOAD: http://Capital-Review.com/register/?so=KWR
CUB DOWNLOAD: http://Capital-Review.com/register/?so=CUB

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Applied Materials, Inc. (NASDAQ:AMAT), MRC Global Inc. (NYSE:MRC), Meritor, Inc. (NYSE:MTOR), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Quaker Chemical Corporation (NYSE:KWR), and Cubic Corporation (NYSE:CUB) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 15th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

APPLIED MATERIALS, INC. (AMAT) REPORT OVERVIEW

Applied Materials' Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Applied Materials reported revenue of $4,014.00MM vs $3,969.00MM (up 1.13%) and analysts estimated basic earnings per share $0.86 vs $0.93 (down 7.53%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Applied Materials reported revenue of $17,253.00MM vs $14,537.00MM (up 18.68%) and analysts estimated basic earnings per share $3.27 vs $3.20 (up 2.19%). Analysts expect earnings to be released on May 16th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was $1.22. The estimated EPS forecast for the next fiscal year is $3.94 and is expected to report on November 21st, 2019.

To read the full Applied Materials, Inc. (AMAT) report, download it here: http://Capital-Review.com/register/?so=AMAT

-----------------------------------------

MRC GLOBAL INC. (MRC) REPORT OVERVIEW

MRC Global's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, MRC Global reported revenue of $1,071.00MM vs $959.00MM (up 11.68%) and analysts estimated basic earnings per share $0.20 vs -$0.03. For the twelve months ended December 31st, 2017 vs December 31st, 2016, MRC Global reported revenue of $3,646.00MM vs $3,041.00MM (up 19.89%) and analysts estimated basic earnings per share $0.28 vs -$1.10. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.13. The estimated EPS forecast for the next fiscal year is $1.52 and is expected to report on February 13th, 2020.

To read the full MRC Global Inc. (MRC) report, download it here: http://Capital-Review.com/register/?so=MRC

-----------------------------------------

MERITOR, INC. (MTOR) REPORT OVERVIEW

Meritor's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Meritor reported revenue of $1,038.00MM vs $903.00MM (up 14.95%) and analysts estimated basic earnings per share $1.06 vs -$0.41. For the twelve months ended September 30th, 2018 vs September 30th, 2017, Meritor reported revenue of $4,178.00MM vs $3,347.00MM (up 24.83%) and analysts estimated basic earnings per share $1.34 vs $3.68 (down 63.59%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.75. The estimated EPS forecast for the next fiscal year is $3.13 and is expected to report on November 13th, 2019.

To read the full Meritor, Inc. (MTOR) report, download it here: http://Capital-Review.com/register/?so=MTOR

-----------------------------------------

CELLDEX THERAPEUTICS, INC. (CLDX) REPORT OVERVIEW

Celldex Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Celldex Therapeutics reported revenue of $0.94MM vs $3.92MM (down 76.02%) and basic earnings per share -$0.04 vs -$0.20. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Celldex Therapeutics reported revenue of $12.74MM vs $6.79MM (up 87.78%) and analysts estimated basic earnings per share -$0.72 vs -$1.27. Analysts expect earnings to be released on March 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$2.55. The estimated EPS forecast for the next fiscal year is -$6.00 and is expected to report on March 6th, 2019.

To read the full Celldex Therapeutics, Inc. (CLDX) report, download it here: http://Capital-Review.com/register/?so=CLDX

-----------------------------------------

QUAKER CHEMICAL CORPORATION (KWR) REPORT OVERVIEW

Quaker Chemical's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Quaker Chemical reported revenue of $222.02MM vs $212.92MM (up 4.28%) and analysts estimated basic earnings per share $1.48 vs $0.84 (up 76.19%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Quaker Chemical reported revenue of $820.08MM vs $746.67MM (up 9.83%) and analysts estimated basic earnings per share $1.53 vs $4.64 (down 67.03%). Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $1.27. The estimated EPS forecast for the next fiscal year is $7.20 and is expected to report on February 28th, 2019.

To read the full Quaker Chemical Corporation (KWR) report, download it here: http://Capital-Review.com/register/?so=KWR

-----------------------------------------

CUBIC CORPORATION (CUB) REPORT OVERVIEW

Cubic's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Cubic reported revenue of $305.26MM vs $248.39MM (up 22.89%) and analysts estimated basic earnings per share -$0.23 vs -$0.36. For the twelve months ended September 30th, 2018 vs September 30th, 2017, Cubic reported revenue of $1,202.90MM vs $1,107.71MM (up 8.59%) and analysts estimated basic earnings per share $0.45 vs -$0.41. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.12. The estimated EPS forecast for the next fiscal year is $2.92 and is expected to report on November 21st, 2019.

To read the full Cubic Corporation (CUB) report, download it here: http://Capital-Review.com/register/?so=CUB

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Nicole Garrens, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.